Want to see SE:XSPRAY full AI Analyst Report?
XSPRAY Stock Chart & Stats
kr15.26
kr0.28(1.83%)
At close: 4:00 PM EDT
kr15.26
kr0.28(1.83%)
Day’s Range― - ―
52-Week Rangekr13.30 - kr62.33
Previous CloseN/A
Volume28.64K
Average Volume (3M)297.70K
Market Cap
kr635.38M
Enterprise Valuekr645.43
Total Cash (Recent Filing)kr179.91M
Total Debt (Recent Filing)kr147.30M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.86
Shares Outstanding47,416,573
10 Day Avg. Volume602,659
30 Day Avg. Volume297,696
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-5.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.2
Revenue Forecast (FY)kr95.00M
Bulls Say, Bears Say
Bulls Say
Proprietary Formulation Technology (HyNap)Xspray's HyNap amorphous dispersion technology is a durable technical differentiator that can materially improve solubility and bioavailability of small-molecule oncology drugs. That capability supports product differentiation, potential patent protection and creates licensing or partnership value over the medium term.
Pipeline Of Reformulated Oncology CandidatesFocusing on reformulating known oncology molecules reduces early clinical and scientific risk versus novel chemistry. This strategy can shorten development timelines, improve probability of commercialization, and enhance partnerability with larger pharma seeking improved, patentable follow-on products.
Substantial Equity Base With Moderate LeverageA relatively large equity cushion versus modest debt gives Xspray balance-sheet flexibility to fund R&D and development programs in the near term. Moderate leverage reduces immediate insolvency risk and supports continued clinical progress before commercialization, assuming burn is managed.
Bears Say
No Reported Revenue; Persistent LossesThe company has no revenue and recurring large net losses, which means the core business is not yet self-sustaining. Over the medium term this forces dependence on external funding, increases dilution risk, and leaves shareholder returns contingent on successful clinical/commercial outcomes.
Sustained Negative Operating And Free Cash FlowMaterial negative operating and free cash flows indicate ongoing cash burn despite some improvement. Persistent outflows constrain strategic options, necessitate recurring financing, and elevate execution risk if capital markets tighten or drug-development timelines extend beyond expectations.
Increasing Leverage And Negative ROERising leverage from previously very low levels, combined with a negative ROE, signals growing reliance on debt and inefficient use of capital. Over time this can raise financing costs, limit flexibility, and pressure equity holders if additional funding is required to sustain development programs.
Xspray Pharma AB News
XSPRAY FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr13.30 and its highest was kr62.33 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr635.38M.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is Nov 04, 2026 which is in 77 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Aug 05, 2026. The company reported -kr0.868 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 47,416,573 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -kr0.868 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.988%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Cantargia AB
―